Praxis Precision Medicines, Inc.

PRAX · Nasdaq · United States

Share price · PRAX

$305.19-64.65 (-17.48%) 3M

close as of 2026-11-18 · 24h delayed · vol 426K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PRAX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026+19.9%
  2. 6 Aug 2026+16.0%
  3. 4 Jun 2026-5.1%

    Nothing announced by PRAX that day or the session before.

  4. 2 Jun 2026-23.0%
  5. 24 Apr 2026+4.6%

    Nothing announced by PRAX that day or the session before.

  6. 31 Mar 2026+16.5%

    Nothing announced by PRAX that day or the session before.

Share of unusual movement by asset

For each asset, the share of PRAX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Relutrigine
events and moves
2shown from 8 days
Ulixacaltamide
events and moves
2shown from 8 days
Elsunersen
events and moves
1shown from 8 days
Vormatrigine
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—78%
Other company news (earnings, financing, releases naming no asset)—8%
Sessions with no dated event—14%

Assets

(4 total)
4Total Assets
0Approved
4Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
SCN2A (antisense knockdown)RNA / oligonucleotide
Epilepsy
Phase 3
Voltage-gated sodium channel (persistent current)Small molecule
EpilepsyDevelopmental and Epileptic Encephalopathies
Phase 3
T-type calcium channelSmall molecule
Essential Tremor
Phase 3
Voltage-gated sodium channel (NaV1.2 / NaV1.6)Small molecule
Epilepsy
Focal Onset Seizures

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
RelutriginePhase 3Developmental and Epileptic Encephalopathy 1
Est. primary completion 2026-12 · NCT07010471 · CT.gov ↗
What to watch
ElsunersenPhase 3Epileptic Encephalopathy, SCN2A Encephalopathy
Est. primary completion 2026-12 · NCT07019922 · CT.gov ↗
What to watch
2027 (1)
January 2027 (1)
VormatriginePhase 3Focal Epilepsy
Est. primary completion 2027-01 · NCT07505004 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
VormatriginePhase 3Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Est. primary completion 2028-05-31 · NCT07287163 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

27 December 2026FDA action dateRelutrigineRelutrigine NDA PDUFA target action date (extended)
US, FDA · FDA · Source ↗
29 January 2027FDA action dateUlixacaltamidePDUFA target action date for ulixacaltamide HCl in essential tremor
US, FDA · FDA · Source ↗

Recent

1 June 2026Topline resultVormatriginePOWER1 Phase 2/3 (NCT06999902) did not meet its primary endpoint
Praxis Precision Medicines · Source ↗
14 April 2026Filing acceptedUlixacaltamideFDA accepted the NDA for ulixacaltamide HCl in essential tremor
US, FDA · Praxis Precision Medicines · Source ↗
6 April 2026Topline resultElsunersen (PRAX-222)EMBRAVE Part A (NCT05737784): elsunersen shows positive topline seizure results
Praxis Precision Medicines, Inc. · Source ↗
30 March 2026Filing acceptedRelutrigineFDA accepts relutrigine NDA for SCN2A and SCN8A DEEs
US, FDA · Praxis Precision Medicines, Inc. · Source ↗
30 March 2026Priority reviewRelutrigineRelutrigine NDA granted priority review
US, FDA · FDA · Source ↗
16 October 2025Topline resultUlixacaltamideEssential3 phase 3 topline
Praxis Precision Medicines · Source ↗

Financial reports

Quarterly & interim (20)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$64M$362M+ $383M short-term inv.$94M-$82M operating cash flowreport ↗
View 19 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$69M$475M+ $284M short-term inv.$84M-$78M operating cash flowreport ↗
2026-Q1—$78M$537M+ $251M short-term inv.$93M-$86M operating cash flowreport ↗
2025-Q3$0$66M$150M+ $118M short-term inv.$74M-$65M operating cash flowreport ↗
2025-Q2$0$63M$158M+ $144M short-term inv.$71M-$55M operating cash flowreport ↗
2025-Q1$0$61M$166M+ $162M short-term inv.$69M-$53M operating cash flowreport ↗
2024-Q4——$216M+ $177M short-term inv.$59M-$56M operating cash flowreport ↗
2024-Q3$0.3M$42M$169M+ $188M short-term inv.$52M-$28M operating cash flowreport ↗
2024-Q2$0.4M$27M$146M+ $207M short-term inv.$33M-$27M operating cash flowreport ↗
2024-Q1$0.4M$27M$152M+ $55M short-term inv.$40M-$21M operating cash flowreport ↗
2023-Q4——$82M+ $0 short-term inv.$27M-$24M operating cash flowreport ↗
2023-Q3$0.5M$17M$102M$25M-$23M operating cash flowreport ↗
2023-Q2$0.8M$26M$125M$34M-$31M operating cash flowreport ↗
2023-Q1$0.7M$26M$81M+ $5.0M short-term inv.$37M-$33M operating cash flowreport ↗
2022-Q4——$62M+ $39M short-term inv.$41M-$29M operating cash flowreport ↗
2022-Q3$0$30M$63M+ $61M short-term inv.$44M-$45M operating cash flowreport ↗
2022-Q2$0$44M$56M+ $109M short-term inv.$60M-$57M operating cash flowreport ↗
2022-Q1$0$53M$78M+ $133M short-term inv.$69M-$54M operating cash flowreport ↗
2021-Q4——$140M+ $106M short-term inv.$59M-$45M operating cash flowreport ↗
2021-Q3—$33M$167M+ $112M short-term inv.$45M-$24M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$267M$358M+ $242M short-term inv.$76M-$249M operating cash flowreport ↗

Praxis Precision Medicines reported revenue of $0M for fiscal 2025, down 100.0% YoY from $8.55M, with R&D spend of $267.12M, up 75.3% YoY. The company held cash and equivalents of $357.75M and reported a net loss of $303.27M, with quarterly net burn of $303.27M.

The clinical-stage CNS biopharmaceutical company submitted NDAs for ulixacaltamide in essential tremor and relutrigine in SCN2A-DEE and SCN8A-DEE, following positive topline Essential3 and EMBOLD registrational results. It expects POWER1 topline results in Q2 2026, EMBRAVE Part A topline in H1 2026, POWER2 and EMBRAVE3 topline results in 2027, and plans a vormatrigine NDA submission in 2027 if the POWER studies are positive.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$8.6M$152M$216M+ $177M short-term inv.$46M-$132M operating cash flowreport ↗
2023-FY$2.5M$87M$82M+ $0 short-term inv.$31M-$111M operating cash flowreport ↗
2022-FY$0$155M$62M+ $39M short-term inv.$54M-$185M operating cash flowreport ↗
2021-FY—$120M$140M+ $106M short-term inv.$42M-$125M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 12 sales ($3.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Mastrocola Lauren · Principal Accounting OfficerAward / grant72$278.91$20KForm 4
2026-11-13Kelly Timothy Edwin · Chief Financial OfficerAward / grant3$278.91$837Form 4
2026-11-13Nemiroff Alex · General Counsel and SecretaryAward / grant49$278.91$14KForm 4
2026-11-13Sniecinski Megan · Chief Operating OfficerAward / grant21$278.91$6KForm 4
2026-07-08Souza Marcio · director, Chief Executive OfficerGift20,521——Form 4
2026-07-08Souza Marcio · director, Chief Executive OfficerGift2,600——Form 4
2026-06-24DeSimone Jill · directorOption exercise8,566$44.25$379KForm 4
2026-06-24DeSimone Jill · directorOption exercise3,034$147.30$447KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 285 reporting institutions held 31.8M shares ($10.0B, 113.9% of shares outstanding).

#InstitutionSharesValue
1JANUS HENDERSON GROUP PLC3,458,863$1.1B
2Orbis Allan Gray Ltd2,472,480$796.6M
3BlackRock, Inc.2,324,929$749.1M
4FMR LLC2,160,943$696.2M
5PERCEPTIVE ADVISORS LLC2,035,986$656.0M
6BAKER BROS. ADVISORS LP1,753,198$564.9M
7VANGUARD CAPITAL MANAGEMENT LLC1,221,944$393.7M
8DEERFIELD MANAGEMENT COMPANY, L.P.963,351$310.4M
9Driehaus Capital Management LLC949,225$305.8M
10Cormorant Asset Management, LP885,500$285.3M
11STATE STREET CORP884,238$284.9M
12MORGAN STANLEY833,491$268.5M
13ADAGE CAPITAL PARTNERS GP, L.L.C.815,739$262.8M
14VANGUARD PORTFOLIO MANAGEMENT LLC756,748$243.8M
15GOLDMAN SACHS GROUP INC710,734$229.0M